(Q30875888)

27 June 2017

1 reference

title

Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project (English)

1 reference

27 June 2017

3

Martijn J Schuemie

0 references

Miriam Sturkenboom

11

object named as

Miriam Sturkenboom

1 reference

27 June 2017

5

Rosa Gini

1 reference

27 June 2017

Vaishali K Patadia

1

1 reference

27 June 2017

Preciosa Coloma

2

1 reference

27 June 2017

Martijn J Schuemie

3

1 reference

27 June 2017

Ron Herings

4

1 reference

27 June 2017

Giampiero Mazzaglia

6

1 reference

27 June 2017

Gino Picelli

7

1 reference

27 June 2017

Carla Fornari

8

1 reference

27 June 2017

Lars Pedersen

9

1 reference

27 June 2017

Johan van der Lei

10

1 reference

27 June 2017

Gianluca Trifirò

12

1 reference

27 June 2017

EU-ADR consortium

13

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 January 2015

1 reference

Expert Review of Clinical Pharmacology

27 June 2017

published in

1 reference

27 June 2017

volume

8

1 reference

27 June 2017

issue

1

1 reference

27 June 2017

page(s)

95-102

1 reference

Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Statin-induced myopathy: the two faces of Janus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

The role of databases in drug postmarketing surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

A review of uses of health care utilization databases for epidemiologic research on therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Disproportionality methods for pharmacovigilance in longitudinal observational databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Safety surveillance of longitudinal databases: methodological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Utilizing Medicare claims data for real‐time drug safety evaluations:is it feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Electronic healthcare databases for active drug safety surveillance: is there enough leverage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Bias: considerations for research practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Bias, prevalence and kappa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Bromocriptine: old drug, new formulation and new indication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2015.992878

10.1586/17512433.2015.992878

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference